The latest price target for Karuna Therapeutics (NASDAQ: KRTX) was reported by HC Wainwright & Co. on September 28, 2023. The analyst firm set a price target for $300.00 expecting KRTX to rise to within 12 months (a possible 77.42% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Karuna Therapeutics (NASDAQ: KRTX) was provided by HC Wainwright & Co., and Karuna Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karuna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karuna Therapeutics was filed on September 28, 2023 so you should expect the next rating to be made available sometime around September 28, 2024.

While ratings are subjective and will change, the latest Karuna Therapeutics (KRTX) rating was a reiterated with a price target of $0.00 to $300.00. The current price Karuna Therapeutics (KRTX) is trading at is $169.09, which is within the analyst’s predicted range.

The latest price target for Karuna Therapeutics (NASDAQ: KRTX) was reported by HC Wainwright & Co. on September 28, 2023. The analyst firm set a price target for $300.00 expecting KRTX to rise to within 12 months (a possible 77.42% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Karuna Therapeutics (NASDAQ: KRTX) was provided by HC Wainwright & Co., and Karuna Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karuna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karuna Therapeutics was filed on September 28, 2023 so you should expect the next rating to be made available sometime around September 28, 2024.

While ratings are subjective and will change, the latest Karuna Therapeutics (KRTX) rating was a reiterated with a price target of $0.00 to $300.00. The current price Karuna Therapeutics (KRTX) is trading at is $169.09, which is within the analyst’s predicted range.

The latest price target for Karuna Therapeutics (NASDAQ: KRTX) was reported by HC Wainwright & Co. on September 28, 2023. The analyst firm set a price target for $300.00 expecting KRTX to rise to within 12 months (a possible 77.42% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Karuna Therapeutics (NASDAQ: KRTX) was provided by HC Wainwright & Co., and Karuna Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karuna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karuna Therapeutics was filed on September 28, 2023 so you should expect the next rating to be made available sometime around September 28, 2024.

While ratings are subjective and will change, the latest Karuna Therapeutics (KRTX) rating was a reiterated with a price target of $0.00 to $300.00. The current price Karuna Therapeutics (KRTX) is trading at is $169.09, which is within the analyst’s predicted range.

The latest price target for Karuna Therapeutics (NASDAQ: KRTX) was reported by HC Wainwright & Co. on September 28, 2023. The analyst firm set a price target for $300.00 expecting KRTX to rise to within 12 months (a possible 77.42% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Karuna Therapeutics (NASDAQ: KRTX) was provided by HC Wainwright & Co., and Karuna Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karuna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karuna Therapeutics was filed on September 28, 2023 so you should expect the next rating to be made available sometime around September 28, 2024.

While ratings are subjective and will change, the latest Karuna Therapeutics (KRTX) rating was a reiterated with a price target of $0.00 to $300.00. The current price Karuna Therapeutics (KRTX) is trading at is $169.09, which is within the analyst’s predicted range.

The latest price target for Karuna Therapeutics (NASDAQ: KRTX) was reported by HC Wainwright & Co. on September 28, 2023. The analyst firm set a price target for $300.00 expecting KRTX to rise to within 12 months (a possible 77.42% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Karuna Therapeutics (NASDAQ: KRTX) was provided by HC Wainwright & Co., and Karuna Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karuna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karuna Therapeutics was filed on September 28, 2023 so you should expect the next rating to be made available sometime around September 28, 2024.

While ratings are subjective and will change, the latest Karuna Therapeutics (KRTX) rating was a reiterated with a price target of $0.00 to $300.00. The current price Karuna Therapeutics (KRTX) is trading at is $169.09, which is within the analyst’s predicted range.

The latest price target for Karuna Therapeutics (NASDAQ: KRTX) was reported by HC Wainwright & Co. on September 28, 2023. The analyst firm set a price target for $300.00 expecting KRTX to rise to within 12 months (a possible 77.42% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Karuna Therapeutics (NASDAQ: KRTX) was provided by HC Wainwright & Co., and Karuna Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karuna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karuna Therapeutics was filed on September 28, 2023 so you should expect the next rating to be made available sometime around September 28, 2024.

While ratings are subjective and will change, the latest Karuna Therapeutics (KRTX) rating was a reiterated with a price target of $0.00 to $300.00. The current price Karuna Therapeutics (KRTX) is trading at is $169.09, which is within the analyst’s predicted range.

The latest price target for Karuna Therapeutics (NASDAQ: KRTX) was reported by HC Wainwright & Co. on September 28, 2023. The analyst firm set a price target for $300.00 expecting KRTX to rise to within 12 months (a possible 77.42% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Karuna Therapeutics (NASDAQ: KRTX) was provided by HC Wainwright & Co., and Karuna Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karuna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karuna Therapeutics was filed on September 28, 2023 so you should expect the next rating to be made available sometime around September 28, 2024.

While ratings are subjective and will change, the latest Karuna Therapeutics (KRTX) rating was a reiterated with a price target of $0.00 to $300.00. The current price Karuna Therapeutics (KRTX) is trading at is $169.09, which is within the analyst’s predicted range.

The latest price target for Karuna Therapeutics (NASDAQ: KRTX) was reported by HC Wainwright & Co. on September 28, 2023. The analyst firm set a price target for $300.00 expecting KRTX to rise to within 12 months (a possible 77.42% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Karuna Therapeutics (NASDAQ: KRTX) was provided by HC Wainwright & Co., and Karuna Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karuna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karuna Therapeutics was filed on September 28, 2023 so you should expect the next rating to be made available sometime around September 28, 2024.

While ratings are subjective and will change, the latest Karuna Therapeutics (KRTX) rating was a reiterated with a price target of $0.00 to $300.00. The current price Karuna Therapeutics (KRTX) is trading at is $169.09, which is within the analyst’s predicted range.